HIV-1 vectors
AssigneeUniversity of Medicine & Dentistry of NJ
InventorsArnold B. Rabson, Hsin-Ching Lin, Marion Bodkin, Roger Strair
Life of this patent
Estimating the term…
Abstract
The present invention pertains to a genetically altered human immunodeficiency virus type 1 (HIV-1) which replicates only in human CD4+ cells that express the Tax protein of Human T-cell Lymphotropic Virus Type I (HTLV-I), wherein the HIV long terminal repeat (LTR) promoter and enhancer sequences (NF-kappa-B and Sp1 binding sites) of the genetically altered human immunodeficiency virus type 1 have been replaced by two copies of the HTLV-I LTR 21 base pair repeat Tax-responsive element (TRE). The present invention also pertains to methods for killing HTLV-1 infected cells in humans with HTLV-1 disease (HTLV-1 tumors and HAM/TSP) with the novel genetically altered human immunodeficiency virus type 1 (HIV-1).
Claims3
An isolated human immunodeficiency virus type 1 (HIV-1) vector altered by having the HIV-1 long terminal repeat (LTR) promoter and enhancer sequences replaced by two copies of the HTLV-I LTR 21 base pair repeat Tax-responsive element (TRE), wherein the promoter and enhancer sequences consist of the NF-K-B and SP1 binding sites, and the altered HIV-1 vector will replicate only in human CD4+ cells that express the Tax protein of HTLV-I.
Dependencies are inferred from the claim text.